1. Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320-330. doi:10.1111/bjh.15109
2. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.Haematologica. 2006;91(4):460-466.
3. Landsteiner K. Ueber Bezie hungenz wischen dem Blut serumund denKorperzellen. Munch Med Wochenschr. 1903;50:1812-1814[German].
4. Clough MC, Richter IM. A study of an auto agglutinin occurring in a human serum. Johns Hopkins HospBull. 1918;29:86-93.
5. Horstmann DM, Tatlock H. Cold agglutinins: a diagnosticaid incertaintypes of primary atypical pneumonia. JAMA. 1943;122(6):369-370.
6. Schubothe H. The cold hemagglutinin disease. Semin Hematol.1966;3(1):27-47.
7. Gertz MA. Cold agglutinin disease. Haematologica. 2006;91(4):439-441.
8. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69(4):258-271.
9. Zilow G, Kirschfink M, Roelcke D. Red cell destruction in cold agglutinin disease. Infusionsther Transfusionsmed. 1994;21(6):410-415.doi:10.1159/000223021
10. Pirozzi, Nicola, AntonellaStoppacciaro, andPaoloMenè. “Dominant C3glomerulopathy: newrolesfor an oldactor in renalpathology.” Journal ofnephrology.2018;31(4):503-510.
11. Lind K, Benzon MW, Jensen JS, Clyde WA Jr. A seroepidemiologicalstudy of Mycoplasma pneumoniae infections in Denmark over the50-year period 1946-1995. Eur J Epidemiol. 1997;13(5):581-586.doi:10.1023/a:1007353121693
12. García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenströmmacroglobulinaemia: presenting features and outcome in a serieswith 217 cases. Br J Haematol. 2001;115(3):575-582. doi:10.1046/j.1365-2141.2001.03144.x
13. Horwitz CA, Moulds J, Henle W, et al. Cold agglutinins in infectiousmononucleosis and heterophil-antibody-negative mononucleosis-likesyndromes. Blood. 1977;50(2):195-202.
14. Karunarathne S, Weerasinghe S, Govindapala D, Fernando H,Jayaratne B. Cold autoimmune haemolytic anaemia secondary toEpstein Barr virus infection presenting with peripheral gangrene; casereport. Thromb J. 2012;10(1):4. Published 2012 Apr 18. doi:10.1186/1477-9560-10-4
15. Brunner B, Kropshofer G, Ellemunter H, Brunner A, Mueller T,Margreiter R, Tzankov A. Severe cold agglutinin disease caused byrecurrent monomorphic Epstein-Barrvirus (EBV) associated post-transplant lymphoproliferativ edisorder (PTLD), clonally related toan EBV negative plasmacytic hyperplasia in a pediatric multi visceralorgan transplant recipient. Pediatr Transplant. 2007;11(5):547-551.
16. Dourakis SP, Alexopoulou A, Stamoulis N, Foutris A, Pandelidaki H,Archimandritis AJ. Acute Epstein-Barr virus infection in two elderlyindividuals. Age Ageing. 2006;35(2):196-198.
17. Feizi, Ten. “Monotypic cold agglutinins in infection by Mycoplasmapneumoniae.” Nature. 1967;215(5100):540-542.
18. Nixon, Christian P.,and Joseph D. Sweeney. “Facilitation oftheclinicaldiagnosis of Mycoplasma pneumoniae by the bloodbank.”Transfusion.2017; 57(11):2564-2564.
19. Khan FY, A yassin M. Mycoplasma pneumoniae associated with severeautoimmune hemolytic anemia: case report and literature review. BrazJ InfectDis. 2009;13(1):77-79.
20. Stein B, DeCredico N, Hillman L. Evaluation of the Direct AntiglobulinTest (DAT) in the Setting of Mycoplasma pneumoniae Infection. JAMA.2018;319(13):1377-1378. doi:10.1001/jama.2018.1969.
21. Terada K, Tanaka H, Mori R, Kataoka N, Uchikawa M. Hemolyticanemia associated with cold agglutinin during chicken pox and areview of the literature. J Pediatr HematolOncol. 1998; 20(2):149-151.
22. Tanaka Y, Masuya M, Katayama N, et al. Development of mixed-type autoimmune hemolytic anemi and Evans’ syndrome followingchicken pox infection in a case of low-titer cold agglutinin disease. Int JHematol. 2006;84(3):220-223.
23. Ciaffoni S, Luzzati R, Roata C, Turrini A, Antonello O, Aprili G.Presence and significance of cold agglutinins in patients with HIVinfection. Haematologica. 1992;77(3):233-236.
24. Kumar A, Shaaban H, Koduru K, Abo S, Sidhom I, Guron G.Citrobacter freundii-induced cold agglutinin hemolysis. AnnHematol.2011;90(7): 855-856.
25. Mori T, Yamada Y, Aisa Y, Uemura T, Ishida A, Ikeda Y, Okamoto S.Cold agglutinin disease associated with adeno virus infection afterallogeneic bone marrow transplantation. Bone MarrowTransplant.2005;36(3):263-264.
26. Schoindre Y, Bolle´e G, Dumont MD, Lesavre P, Servais A. Coldagglutinin syndrome associated with a 2009 influenza A H1N1infection. Am J Med. 2011;124(2):e1-e2.
27. König AL, Schabel A, Sugg U, Brand U, Roelcke D. Autoimmunehemolytic anemia caused by IgG lambda-monotypic cold agglutinins ofanti-Pr specificity after rubella infection. Transfusion. 2001;41(4):488-492. doi:10.1046/j.1537-2995.2001.41040488.x
28. Oshima, Miki, et al. “Low-titer cold agglutinin disease with systemicsclerosis.”Internal medicine.2004;43(2):139-142.
29. Honne, Kyoko, et al. “Glucocorticoid-responsivecoldagglutinindiseasein a patientwithrheumatoidarthritis.”Case reports in rheumatology2015(2015).
30. Cholongitas E, Ioannidou D. Acrocyanosisduetocoldagglutinins in apatientwithrheumatoidarthritis. J ClinRheumatol. 2009;15(7):375.
31. Kotani T, Takeuchi T, Kawasaki Y, et al. Successfultreatment ofcoldagglutinindiseasewith anti-CD20 antibody (rituximab) in apatientwithsystemiclupuserythematosus. Lupus. 2006;15(10):683-685.
32. Srinivasan N, Oswal A, Garg S, Nahar J, Gosmonova A, Nahar R. Coldagglutinin induced hemolysis in a newly diagnosed systemic lupuserythematosus. Am J Med Sci. 2010;339(3):270-273.
33. Wen, Wen, et al. «Clinical and serologic features of primary Sjögren’ssyndrome concomitant with autoimmune hemolytic anemia: A large-scale cross-sectional study.» Clinical rheumatology. 34.11(2015):1877-1884.
34. Qiao, Lin, et al. «Agranulocytosis and mixed-type autoimmunehemolytic anemia in primary sjögren›s syndrome: a case report andreview of the literature. International Journal of Rheumatic Diseases2016:19(12):1351-1353.
35. Kikawada, Masayuki, et al. “Autoimmunehemolyticanemia inanntwithprimarySjögren’ssyndrome.” Internalmedicine. 2005;44(12):1312-1315.
36. Crisp, David, and WaldemarPruzanski. “B-cell neoplasms withhomogeneous cold-reacting antibodies (cold agglutinins).”TheAmerican journal of medicine. 1982;72(6):915-922.
37. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood.2013;122(7):1114-1121. doi:10.1182/blood-2013-02-474437
38. Cao L, Kaiser P, Gustin D, Hoffman R, Feldman L.Coldagglutinindisease in a patientwithuterinesarcoma. Am J MedSci.2000;320(5):352-354.
39. Al-Matham K, Alabed I, Zaidi SZ, Qushmaq KA. Coldagglutinindiseasein fibrolamellarhepatocellularcarcinoma: a rareassociationwith ararecancervariant. AnnSaudiMed. 2011;31(2):197-200.
40. Carlsson J, Ba¨tge R, Rahlf G, Tebbe U.Coldagglutinindiseaseandmetastaticmelanoma [in German]. MedKlin(Munich). 1994;89(6): 343-345
41. Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev.2008;22(1):1-15. doi:10.1016/j.blre.2007.08.002
42. Dacie JV. The Haemolytic Anaemias. In: The Auto-immune HaemolyticAnaemias. 3rd ed. Vol. 3. Edinburgh, Scotland: Churchill Livingstone;1992: 502-520.
43. Nydegger UE, Kazatchkine MD, Miescher PA. Immunopathologic andclinical features of hemolytic anemia due to cold agglutinins. SeminHematol. 1991;28(1):66-77.
44. Chandesris MO, Schleinitz N, Ferrera V, et al. Coldagglutinins,clinicalpresentationandsignificance; retrospectiveanalysis of 58patients [in French]. RevMedInterne. 2004;25(12): 856-865.
45. Baines, Andrea C.,and Robert A. Brodsky. “Complementopathies.”Bloodreviews. 2017;31(4):213-223.
46. Zoppi, M., et al. “Reduction of plasma cold agglutinin titers by meansof plasmapheresis to prepare a patient for coronary bypass surgery.”Transfusion Medicine and Hemotherapy. 1993;20:19-22.
47. Siami FS, Siami GA. A last resort modality using cryofiltrationapheresis for the treatment of cold hemagglutinin disease in aVeterans Administration hospital. Ther Apher Dial. 2004;8(5):398-403.doi:10.1111/j.1526-0968.2004.00182.x
48. Kanemitsu S, Onoda K, Yamamoto K, Shimpo H. Simple preoperativemanagement for cold agglutinins before cardiac surgery. J ThoracCardiovasc Surg. 2010;140(5):e73-e74. doi:10.1016/j.jtcvs.2010.06.030
49. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab inadult patients with idiopathic autoimmune hemolytic anemia:clinical efficacy and biologic studies. Blood. 2012;119(16):3691-3697.doi:10.1182/blood-2011-06-363556
50. Berentsen S, Randen U, Vågan AM, et al. High response rate anddurable remissions following fludarabine and rituximab combinationtherapy for chronic cold agglutinin disease. Blood. 2010;116(17):3180-3184. doi:10.1182/blood-2010-06-288647
51. Berentsen, Sigbjørn, et al. “Bendamustine plus rituximab for chroniccold agglutinin disease: results of a Nordic prospective multicentertrial.” Blood (2017): blood-2017.
52. Gueli A, Gottardi D, Hu H, Ricca I, De Crescenzo A, Tarella C.Efficacy of rituximab-bendamustine in cold agglutinin haemolyticanaemia refractory to previous chemo-immunotherapy: a case report.Blood Transfus. 2013;11(2):311-314. doi:10.2450/2012.0166-1
53. Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood.2010;115(4):915. doi:10.1182/blood-2009-09-242917
54. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primarychronic cold agglutinin disease: a prospective study of 37 courses oftherapy in 27 patients. Blood. 2004;103(8):2925-2928. doi:10.1182/blood-2003-10-3597.
55. Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomibin anemic patients with relapsed cold agglutinin disease: a phase 2prospective GIMEMA study. Blood. 2018;132(5):547-550. doi:10.1182/blood-2018-03-835413
56. Izumi M, Tsunemine H, Suzuki Y, et al. Successful treatment ofrefractory cold hemagglutinemia in MYD88 L265P mutation-negativeWaldenström’s macroglobulinemia with bortezomib. Int J Hematol.2015;102(2):238-243. doi:10.1007/s12185-015-1775-1773
57. Adam, Z., et al. “Cold agglutinin disease-no response to glucocorticoidsand rituximab, what treatment is best for the 3rd line of therapy? Casereport and review of the literature.” Vnitrni lekarstvi 2013;59(9):828-840.
58. Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of theserine protease C1s, prevents complement activation induced bycold agglutinins. Blood. 2014;123(26):4015-4022. doi:10.1182/blood-2014-02-556027
59. Derhaschnig, Ulla, et al. “Combined integrated protocol/basket trialdesign for a first-in-human trial.” Orphanet journal of rare diseases2016;11(1):134.
60. Wahrmann, Markus, et al. “Effect of the Anti-C1s HumanizedAntibody TNT 009 and Its Parental Mouse Variant TNT 003 on HLAAntibody-Induced Complement Activation—A Preclinical In VitroStudy.” American Journal of Transplantation. 2017;17(9):2300-2311
61. Sharp, Julia A., et al. “Peptide inhibitor of complement c1, a novelsuppressor of classical pathway activation: mechanistic studies andclinical potential.” Frontiers in immunology 5 (2014): 406.
62. Röth, Alexander, et al. “Eculizumab in cold agglutinin disease(DECADE): an open-label, prospective, bicentric, nonrandomizedphase 2 trial.” Blood advances. 2018;2(19):2543-2549
63. Röth A, Barcellini W, D’Sa S, et al. Sutimlimab in Cold AgglutininDisease. N Engl J Med. 2021;384(14):1323-1334
64. Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M. Novel insightsinto the treatment of complement-mediated hemolytic anemias. TherAdv Hematol. 2019;10:2040620719873321. Published 2019 Sep 9